NovaBay Pharmaceuticals, Inc. NBY NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score

27/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

NovaBay Pharmaceuticals, Inc. (NBY) has a negative trailing P/E of -0.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -349.31%.

Criteria proven by this page:

VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -0.3); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -349.31%).
Trailing Earnings Yield -349.31% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.

Overall SharesGrow Score: 25/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

27/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

✗

FUTURE

20/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

HEALTH

50/100

Debt-to-Equity & liquidity

→ Health

MOAT

50/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — NBY

Valuation Multiples

P/E (TTM)-0.3

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio-0.42

P/S Ratio0.00

EV/EBITDA-4.9

Per Share Data

EPS (TTM)$-5.73

Book Value / Share$-3.92

Revenue / Share$0.00

FCF / Share$-1.45

Yields & Fair Value

Earnings Yield-349.31%

Dividend Yield0.00%

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2016	-95.5	-1.88	176.79	105.52	-
2017	-199.2	4.52	568.58	80.90	-
2018	-41.9	2.10	55.41	21.95	-
2019	-33.0	-1.31	327.72	48.32	-
2020	-55.4	1.58	49.62	61.53	-
2021	-62.6	1.20	35.87	35.76	-
2022	-4.8	-0.05	4.85	3.55	-
2023	-2.2	0.04	6.46	2.05	-
2024	-7.1	0.07	-396.20	5.23	-
2025	-7.4	-0.01	-7.19	0.00	2.93%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-1,047.97	$11.9M	$-13.15M	-110.5%
2017	$-591.81	$18.23M	$-7.4M	-40.6%
2018	$-564.17	$12.51M	$-6.55M	-52.3%
2019	$-593.63	$6.6M	$-10.49M	-158.9%
2020	$-385.53	$9.93M	$-11.04M	-111.1%
2021	$-184.09	$8.42M	$-6.56M	-77.9%
2022	$-353.59	$14.4M	$-16.27M	-112.9%
2023	$-138.65	$10.46M	$-9.64M	-92.2%
2024	$-2.53	$9.78M	$-7.22M	-73.8%
2025	$-3.80	$0.00	$-22.14M	-